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Abstract 
We present the case of a 52 years old woman
who developed multiple brain metastasis after
cystectomy  with  anterior  exenteration  and
chemotherapy.  She  received  whole-brain
radiotherapy with 20 gray in 5 sessions. On
magnetic  resonance  imaging  8  weeks  after
radiotherapy she showed a regression of some
lesions while others responded only partially.
This case-report and a review of the literature
show the importance of aggressive local treat-
ment in patients with brain metastasis from
urachal carcinoma.
Introduction
Bladder adenocarcinoma is an uncommon
malignant tumor accounting for less than 2%
of all the malignant urinary bladder tumours. It
includes primary bladder adenocarcinoma and
urachal  adenocarcinoma.  Urachal  carcinoma
is a carcinoma derived from urachal remnants.
The vast majority of urachal carcinomas are
adenocarcinomas;  but  urothelial,  squamous
and other carcinomas may also occur. Urachal
adenocarcinoma is far less common than non-
urachal adenocarcinoma of the bladder, only
10% are of urachal origin and patients are usu-
ally younger.1 Urachal adenocarcinoma occurs
slightly more in men than in women, with a
ratio, of about 1.8:1. A recent population based
analysis  from  a  neighboring  province
(Ontario) identified 40 cases in 25 years. The
incidence of detection was therefore 0.18 new
cases per 100,000 residents yearly, the median
age was 52 years.2
We report a case of brain metastasis in a
patient  with  poor  response  to  whole  brain
radiotherapy.
Case Report
A 52 years old women had a partial cystecto-
my  of  the  dome  of  the  bladder  followed  9
months  later  by  a  cystectomy  with  anterior
exenteration. During follow-up presence of a
pulmonary  nodule  measuring  2.5  cm  was
noted. The patient had stopped smoking about
20 years ago after a 10 pack year exposure. A
transthoracic core biopsy confirmed the histol-
ogy as being identical to that of the tumor in
the bladder. Histology revealed an adenocarci-
noma of mixed type, with enteric, mucinous,
and signet ring cells components positive for
CK7, CK 20, CDX-2 and B-catenin (membra-
nous and cytoplasmic staining with no nuclear
expression) and negative for TTF-1, EGFR-wild
type and without ALK-1 rearrangement. Within
the clinical context of a mass at the bladder
dome, the diagnosis of urachal carcinoma was
therefore the most probable.The patient then
received 4 cycles of chemotherapy containing
5-FU, Leucovorin, Cisplatin and Gemcitabine.3
Four months later the patient received pelvic
radiotherapy  (20  gray  in  5  sessions)  for
enlarged  pelvic  lymphnodes  with  intrapelvic
nerve  compression  (max  4.4  cm).  During
radiotherapy she presented with neurological
symptoms. A contrast enhanced magnetic res-
onance  imaging  (MRI)  confirmed  the  pres-
ence  of  6  intracerebral  lesions  showing
intense enhancement and large surrounding
edema. The patient then received whole-brain
radiotherapy with 20 gray in 5 sessions. Less
than a month after radiotherapy she presented
with massive neurological deterioration. A sec-
ond MRI 8 weeks later showed a regression of
some  lesions  while  others  became
hypointense after injection of gadolinium. The
main lesion decreased from 3.5 to 3.26 cm and
showed signs of intralesional hemorrhage as
well as peripheral enhancement. Other lesions
also  became  hypo-intense  and  showed
enhancement.
Shortly after she developed pancolitis and
pelvic,  retroperitoneal,  hepatic  progression
associated with radiological signs of peritoneal
carcinomatosis. Considering a decline to a per-
formance  status  of  4  of  the  Eastern
Cooperative Oncology Group (ECOG) scale, it
was decided to continue palliative care with no
further  anticancer  treatment.  She  died  less
than 2 months after the second MRI.
Discussion
Known prognostic factors in urachal carci-
noma are operative treatment, well differenti-
ated  tumors,  T-stage  and  negative  surgical
margins.4-6Compared to non-urachal adenocar-
cinoma, urachal carcinoma are more frequent
in women, although another report found the
contrary.5 Patients are usually younger at diag-
nosis and have a better prognosis7 than with
non-urachal  adenocarcinoma.  Outcome  in  a
non-metastatic setting with partial cystectomy
and  umbilectomy  seems  to  show  the  same
results as radical cystectomy.6,8 As long as the
cancer  hasn’t  invaded  abdominal  organs  or
seeded the peritoneal cavity, a majority can be
cured.6 Therefore, Herr et al.6 suggest replac-
ing the different staging systems for urachal
carcinoma  by  simply  dichotomizing  patients
on the surgical specimen into confined to the
urachus,  bladder  and  perivesical  tissue  vs.
intraperitoneal spread of disease. 
Metastatic disease is very aggressive. Herr
et al.6 reported a median overall survival from
the  diagnosis  of  metastatic  disease  of  17
months. And Ashley et al.4 reported that most
patients died from their metastatic disease a
median of just over 1 year from the diagnosis
of  metastatic  disease.  Our  here  described
patient had aggressive disease that lead to her
death about 15 months from the diagnosis of
metastatic disease and less than one year after
the  start  of  chemotherapy.  The  value  of
chemotherapy  in  the  metastatic  setting  is
unclear. Most chemotherapy regimens are 5-
FU and Cisplatin-based,9 as our patient.
The M.D. Anderson analysis of 42 cases in 16
years found a median survival of 46 months and
24 months for patients with metastatic disease.3
There is very little literature about brain metas-
tasis  in  urachal  carcinoma.  Brain  metastasis
are not rare; M.D. Anderson reported that 5/26
patients with metastatic urachal carcinoma had
brain metastasis.9 This report did unfortunately
not mention the treatment modality for their
brain disease. And the Mayo Clinic reviewed 66
patients,  6%  (n=2)  of  the  patients  with
metastatic  disease  had  brain  metastasis.4Our
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present case underlines the aggressiveness of
brain metastasis in urachal carcinoma and the
poor  response  to  conventional  whole  brain
External  Beam  Radiation  Therapy  (EBRT)  in
this particular case. Our experience is support-
ed by the report from Tewar et al.10Their patient
had  a  resected  singular  metastasis  without
adjuvant  EBRT.  The  patient  later  died  of
extracranial disease. And Kaido et al.11treated a
patient with gamma knife radiosurgery (GKS)
and surgical resection. On MRI 6 weeks post
GKS  the  lesions  disappeared  but  on  MRI  3
months  after  GSK  there  were  10  different
lesions, treated again with GKS.
Conclusion
We  believe  it  is  important  to  treat  brain
metastasis  aggressively  with  either  surgery
followed by whole brain EBRT or with whole
brain  EBRT  and  stereotactic  radiosurgery  to
increase local control.
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